1. Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
   Synnøve Nymark Aasen et al, 2019, International Journal of Molecular Sciences CrossRef
2. Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin
   Vittorio Castaldo et al, 2023, Journal of Experimental & Clinical Cancer Research CrossRef
3. Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability
   Alice Raineri et al, 2019, International Journal of Molecular Sciences CrossRef
4. Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications
   Monica Marzagalli et al, 2019, Seminars in Cancer Biology CrossRef
5. Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways
   Marina Pisano et al, 2019, Metallomics CrossRef
6. Melanoma cells with acquired resistance to vemurafenib have decreased autophagic flux and display enhanced ability to transfer resistance
   Celia N. Pérez et al, 2023, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
7. Iodinated 4,4’‐Bipyridines with Antiproliferative Activity Against Melanoma Cell Lines
   Paola Peluso et al, 2024, ChemMedChem CrossRef
8. Mechanisms of Resistance to Targeted Therapies in Skin Cancers
   Anna M. Czarnecka et al, 2021, New Therapies in Advanced Cutaneous Malignancies CrossRef
9. Reactive Oxygen Species Regulation of Chemoresistance and Metastatic Capacity of Melanoma: Role of the Cancer Stem Cell Marker CD271
   Francesca Beretti et al, 2023, Biomedicines CrossRef
10. CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells
    Agathe Reigstad et al, 2022, PLOS ONE CrossRef
11. Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma
    Zili Zhai et al, 2020, Cancers CrossRef
12. Allgemeines
    Lucie Heinzerling et al, 2019, Medikamentöse Tumortherapie in der Dermato-Onkologie CrossRef
13. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
    Ilaria Proietti et al, 2020, Cancers CrossRef
14. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
    Ewelina Dratkiewicz et al, 2019, International Journal of Molecular Sciences CrossRef
15. The miRNAs Role in Melanoma and in Its Resistance to Therapy
    Francesca Varrone et al, 2020, International Journal of Molecular Sciences CrossRef
16. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells
    Hillary H. Le et al, 2021, EBioMedicine CrossRef
17. Targeting cancer stem cells by melatonin: Effective therapy for cancer treatment
    Nazila Fathi Maroufi et al, 2020, Pathology - Research and Practice CrossRef
18. Chloroacridine derivatives as potential anticancer agents which may act as tricarboxylic acid cycle enzyme inhibitors
    Miroslawa Cichorek et al, 2020, Biomedicine & Pharmacotherapy CrossRef
19. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression
    Eszter Molnár et al, 2019, International Journal of Molecular Sciences CrossRef
20. Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
    Shujing Liu et al, 2017, Oncotarget CrossRef
21. Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma
    Marie Angèle Cucci et al, 2023, Antioxidants CrossRef
22. Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
    Stephen A. Luebker et al, 2019, Frontiers in Oncology CrossRef